Wide Open Agriculture Cuts Royalty Costs to Sharpen Lupin Protein Margins at Scale
WOA and Curtin University agree simplified royalty terms to sharpen lupin protein economics
Wide Open Agriculture (ASX: WOA) has renegotiated its royalty terms with Curtin University under its exclusive global licence for the company’s proprietary lupin protein technology. A single flat 3.5% of net sales replaces the previous tiered structure, which combined a per-tonne fee with a 12.5% high-value tier that escalated costs as product values increased. The global scope, exclusivity, and all other material terms of the licence remain unchanged.
When big ASX news breaks, our subscribers know first
Understanding the royalty change — what shifted and why it matters
From a tiered structure to a single flat rate
A sales-based royalty is a fee paid to a licensor calculated as a percentage of revenue generated from selling a licensed product. For a scaling business, royalty structure complexity can distort financial planning and erode competitiveness at higher price points, making simplification a meaningful operational improvement.
Under the previous terms, WOA paid $120 per tonne of lupin protein isolate, plus 12.5% of sales revenue above $6,000 per tonne. This meant that higher-value product carried a disproportionately heavier royalty burden, creating an escalating cost curve as the business grew. The amended structure replaces this entirely with a flat 3.5% of net sales, applied consistently regardless of price point.
| Royalty Component | Previous Terms | Amended Terms | What Changed | Why It Matters |
|---|---|---|---|---|
| Sales-based royalty | $120/tonne of lupin protein isolate, plus 12.5% of sales revenue above $6,000/tonne | 3.5% of net sales (single flat rate) | Per-tonne fee and high-value tier both removed | Materially lower effective rate at commercial price points; removes cost escalation at scale |
| Sub-licence revenue royalty | 12.5% of revenue derived from sub-licences | 12.5% (unchanged) | No change | Sub-licensing economics remain consistent with original agreement |
| Minimum annual royalty | Three-year average ramping from $50,000 to $75,000 per annum | $50,000 per annum (flat) | Peak obligation reduced from $75,000 to $50,000 | Reduces fixed royalty floor, improving early-stage project economics |
The practical benefits of the flat structure can be summarised across three areas:
- Cleaner financial modelling as WOA progresses its scale-up plans
- More competitive customer pricing at higher production volumes
- Simplified long-term scale-up decisions with a predictable, consistent royalty basis
Aligned interests — how better WOA economics benefit Curtin too
A structure designed for scale, not just savings
The amended terms are designed to align both parties’ commercial interests rather than simply reducing WOA’s cost base. A lower effective royalty rate gives WOA the ability to compete more aggressively on pricing in the global protein market, which could support larger customer contracts and higher production volumes. Higher volumes, in turn, mean greater absolute royalty revenue flowing to Curtin University, meaning both organisations stand to benefit as WOA scales.
The amendment also reflects Curtin University’s ongoing commitment to WOA’s commercialisation pathway and the continuing collaboration between the two organisations across technology development, know-how, and R&D. The original licence agreement, dated 18 May 2020, granted WOA exclusive global rights to develop and commercialise a novel protein technology derived from Australian sweet lupin. This amendment builds on that foundation without altering its scope.
CEO Craig Swan
“Curtin University has been a valued partner since the outset of this program, and this amendment reflects that partnership in action. The simplified royalty structure gives WOA a clearer basis for long-term planning and supports our focus on commercialising the whole lupin seed.
We are grateful to Curtin for their continued support of our commercialisation pathway, and we look forward to building on this relationship as we progress toward scaled production.”
Since the original licence was established, WOA has advanced its proprietary protein technology from lab scale to commercial sales. The company is now progressing a scaled production strategy targeting full monetisation of the whole lupin seed, covering protein, oil, and fibre across multiple applications.
The next major ASX story will hit our subscribers first
What’s next for WOA’s lupin protein scale-up
The amended royalty terms are intended to function as a commercial enabler for WOA’s next phase of growth, improving project economics per tonne of product sold and strengthening the company’s ability to secure larger customer contracts.
WOA’s forward focus, as outlined in the announcement, centres on three areas:
- A scaled production strategy targeting full monetisation of the whole lupin seed
- Protein, oil, and fibre applications across food, beverage, cosmetics, and nutraceutical sectors
- Long-term planning supported by a simplified, predictable royalty structure
It is worth noting that the licence scope, exclusivity, and global territorial reach are unchanged. WOA retains an exclusive global licence to its proprietary method for creating plant-based protein from Australian sweet lupin and its use as a plant-based protein food ingredient, with the right to develop and launch products across multiple food categories.
The structural improvement positions WOA more competitively as demand for plant-based protein ingredients continues to grow across global food and beverage markets.
Don’t Miss the Next Consumer Staples Breakout on the ASX
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market across Tech, Healthcare, Consumer, and more. Click the “Free Alerts” button at the top of the page to start receiving alerts the moment news breaks.